Invokana Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Canagliflozin hemihydrate

Indications/Uses

Adjunct to diet & exercise to improve glycemic control in adult patients w/ type 2 DM for whom metformin is inappropriate due to contraindications or intolerance. Combination w/ metformin or sulfonylurea in adult patients w/ type 2 DM; combination w/ metformin & either sulfonylurea or pioglitazone in adult patients w/ type 2 DM; as add-on combination therapy w/ insulin (w/ or w/o metformin) in adult patients w/ type 2 DM; as an adjunct to diet, exercise & standard of card therapy to reduce risk of major adverse CV events in adult patients w/ type 2 DM; as an adjunct to diet, exercise & standard of care therapy to reduce risk of end-stage kidney disease, doubling of serum creatinine & CV death in adult patients w/ type 2 DM & diabetic nephropathy w/ albuminuria (>33.9 mg/mmol).

Click to view Invokana detailed prescribing information

Dosage/Direction for Use

Initially 100 mg once daily, may be increased to 300 mg once daily if necessary.

Click to view Invokana detailed prescribing information

Overdosage

View Invokana overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food: Take preferably before the 1st meal of the day.

Contraindications

Hypersensitivity. Patients w/ eGFR <60 mL/min/1.73 m² or CrCl <60 mL/min.

Click to view Invokana detailed prescribing information

Special Precautions

Not recommended for use in patients w/ type 1 diabetes. Not to be used for treatment of diabetic ketoacidosis. Patients at risk for AR related to vol depletion. Patients w/ already elevated haematocrit, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Moderate renal impairment. Not to be used during pregnancy & lactation.

Click to view Invokana detailed prescribing information

Use In Pregnancy & Lactation

Click to view Invokana detailed prescribing information

Adverse Reactions

Hypoglycaemia in combination w/ insulin or sulphonylurea, vulvovag candidiasis, UTI, polyuria, pollakiuria.

Click to view Invokana detailed prescribing information

Drug Interactions

Decreased exposure w/ cholestyramine. Add to the effect of diuretics, inulin & insulin secretagogues eg, sulphonylureas; enzyme inducers (eg, St. John's wort, rifampicin, barbiturates, phenytoin, carbamazepine, ritonavir, efavirenz). Increased AUC & C_max of digoxin.

Click to view Invokana detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Invokana detailed prescribing information

Storage

View Invokana storage conditions for details to ensure optimal shelf-life.

Description

View Invokana description for details of the chemical structure and excipients (inactive components).

Action

View Invokana mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antidiabetic Agents

ATC Classification

A10BK02 - canagliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.

Regulatory Classification

Presentation/Packing

Form

Invokana FC tab 100 mg

Packing/Price

30's

Form

Invokana FC tab 300 mg

Packing/Price

30's

Invokana

canagliflozin

Manufacturer:

Janssen

Distributor:

Zuellig Pharma

Marketer:

Merck